Physicians' Academy for Cardiovascular Education

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?

June 5, 2017 - ERA-EDTA, Madrid Spain - Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA

During a satellite symposium at the ERA-EDTA in Madrid, Spain, organised by PACE-CME, Kamyar Kalantar-Zade, MD shows the data based on which alkaline phosphatase is emerging as a prognostic biomarker of CV events. BET inhibition with apabetalone lowers ALP, and may thus be a promising therapeutic strategy.

Video navigation menu

  • Unmet needs in the management of diabetes and CKD may be met by novel epigenetic therapies that alter transcription of several genes simultaneously.  0:30
  • BET inhibition with apabetalone reduces calcification in in vitro models, likely by downregulation of alkaline phosphatase (ALP) expression 3:31
  • ALP has been linked to mortality, CV disease and diabetes, especially in CKD patients 6:48
  • SInce ALP emerges as an important prognostic biomarker of CV events, can it be lowered in vivo, aiming to reduce events? 11:54
  • Hypothetical model based on in vitro and in vivo data of how BET inhibition may lower ALP expression with potential CV benefit 17:16

Educational information

Disclosures

Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA

CME Accreditation

This lecture was part of a CME accredited symposium: Managing CKD, Diabetes & CVD: Is epigenetics a new way forward? held at ERA-EDTA in Madrid, Spain.

Funding

The symposium was supported by an unrestricted educational grant from Resverlogix Corp